Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

267
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
267
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
140
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

306
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
306
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

340
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
340
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

290
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
290

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months.

Epilepsia·2026
Same author

Safety, feasibility, and technique of stereo-electroencephalography in children younger than 3 years.

Journal of neurosurgery. Pediatrics·2026
Same author

Supraorbital craniotomy for focal frontal epilepsy via eyebrow incision and guided by in situ stereo-EEG electrodes: illustrative case.

Journal of neurosurgery. Case lessons·2025
Same author

Outcomes of Early-Life Focal Cortical Dysplasia-Related Epilepsy: A PERC Surgery Study.

Neurology. Clinical practice·2025
Same author

Optimal stimulation of the thalamic centromedian nucleus in children with Lennox-Gastaut syndrome: patient series.

Journal of neurosurgery. Case lessons·2025
Same author

Intracranial neuromodulation for pediatric drug-resistant epilepsy: early institutional experience.

Frontiers in surgery·2025

Related Experiment Video

Updated: May 25, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K

Neuromodulation in pediatric drug-resistant epilepsy.

Ann Hyslop1, Marytery Fajardo2

  • 1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 750 Welch Rd, Palo Alto, CA 94304, United States.

Epilepsy & Behavior : E&B
|February 27, 2025
PubMed
Summary

This review covers three neuromodulation devices for drug-resistant epilepsy in children: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. It details their mechanisms, trials, efficacy, and adverse effects.

Keywords:
Deep brain stimulationNeuromodulationPediatric epilepsy surgeryRefractory epilepsyResponsive neurostimulationVagus nerve stimulation

More Related Videos

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

6.7K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K

Related Experiment Videos

Last Updated: May 25, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K
Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain
08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

6.7K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.9K

Area of Science:

  • Neurology
  • Biomedical Engineering
  • Pediatric Epilepsy

Background:

  • Refractory epilepsy affects many children, often inadequately managed by medication alone.
  • Neuromodulation offers alternative treatment strategies for difficult-to-treat epilepsy cases.
  • Several neuromodulation devices are commercially available, with increasing application in pediatric populations.

Purpose of the Study:

  • To provide a high-level overview of three FDA-approved neuromodulation devices for refractory epilepsy.
  • To highlight the application and considerations of these devices in pediatric patients.
  • To summarize the mechanisms, clinical evidence, and safety profiles of available neuromodulation therapies.

Main Methods:

  • Review of pivotal clinical trials and regulatory submissions for vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation.
  • Synthesis of data on device mechanisms, efficacy outcomes, and adverse event profiles.
  • Focus on studies involving pediatric populations with refractory epilepsy.

Main Results:

  • Vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation demonstrate varying degrees of seizure reduction in pediatric epilepsy.
  • Each modality has distinct mechanisms of action and implantation procedures.
  • Common adverse effects are generally manageable, though specific risks are associated with each device.

Conclusions:

  • Neuromodulation represents a significant advancement in managing refractory epilepsy in children.
  • The choice of device depends on individual patient factors, epilepsy characteristics, and physician expertise.
  • Continued research is essential to optimize neuromodulation strategies and expand their use in pediatric epilepsy.